Interview: Excellence in stem cell treatments
Acquisition of GST reflects the enormous potential of biotechnology research to provide breakthrough therapies for major diseases. Learn more.
Search
Development Biotechnology sustainable cell culture
Boehringer Ingelheim refines its bioprocess technology operations in Animal Health with greater focus on environmental sustainability to reduce footprint.
Stem cells a new frontier
Stem cells may be a game changer for the development of new veterinary treatments. Click here to read this story and find out more information.
1948-1988
Following the death of Albert Boehringer (1861-1939), his two sons and his son-in-law Julius Liebrecht took over this family company. Learn more.
Advances in vectored vaccines for poultry
Click here to learn how vaccine design technologies have made huge advances in recent years to overcome challenges that conventional vaccines do not meet.
1988-2015
Following the death of Hubertus Liebrecht (1991), the owning family made some fundamental decisions regarding the company’s alignment. Learn more here.
1885-1948
In 1885, Albert Boehringer purchased a small tartar factory in the Rhine-Hessian village of Nieder-Ingelheim. Click here to learn more about our history.